{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:53:03Z","timestamp":1790268783861,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115805","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T01:59:57Z","timestamp":1695088797000},"page":"115805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Exploring novel anticancer pyrazole benzenesulfonamides featuring tail approach strategy as carbonic anhydrase inhibitors"],"prefix":"10.1016","volume":"261","author":[{"given":"Rehab F.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa R.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa M.","family":"Abdelgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-3847","authenticated-orcid":false,"given":"Mona F.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115805_bib1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1080\/14756366.2019.1664501","article-title":"Activation of \u03b1-, \u03b2-, \u03b3-\u03b4-, \u03b6-and \u03b7-class of carbonic anhydrases with amines and amino acids: a review","volume":"34","author":"Akocak","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib2","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115805_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2013.798648","article-title":"Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013)","volume":"23","author":"Monti","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115805_bib4","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.2174\/138161210793429841","article-title":"Recent advances in structural studies of the carbonic anhydrase family: the crystal structure of human CA IX and CA XIII","volume":"16","author":"Supuran","year":"2010","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2023.115805_bib5","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1021\/jm701526d","article-title":"Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs","volume":"51","author":"Thiry","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2174\/156802607780636690","article-title":"Current topics in medicinal chemistry","volume":"7","author":"Supuran","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib7","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1111\/jcmm.17027","article-title":"Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions","volume":"25","author":"Chen","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115805_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1215\/S1152851705000025","article-title":"Expression of hypoxia-inducible carbonic anhydrases in brain tumors","volume":"7","author":"Proescholdt","year":"2005","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2023.115805_bib9","first-page":"2827","article-title":"Identification of the MN\/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney","volume":"57","author":"Liao","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115805_bib10","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1073\/pnas.95.13.7608","article-title":"Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers","volume":"95","author":"T\u00fcreci","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2023.115805_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1215\/15228517-2007-065","article-title":"Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas","volume":"10","author":"Haapasalo","year":"2008","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2023.115805_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0046-8177(96)90062-3","article-title":"Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia","volume":"27","author":"Resnick","year":"1996","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2023.115805_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-213X-9-22","article-title":"Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development","volume":"9","author":"Liao","year":"2009","journal-title":"BMC Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115805_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","article-title":"How many carbonic anhydrase inhibition mechanisms exist?","volume":"31","author":"Supuran","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib15","doi-asserted-by":"crossref","first-page":"190407","DOI":"10.1098\/rsos.190407","article-title":"Kinetic study of catalytic CO2 hydration by metal-substituted biomimetic carbonic anhydrase model complexes","volume":"6","author":"Park","year":"2019","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.ejmech.2023.115805_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(96)00198-2","article-title":"Structure and mechanism of carbonic Anhydrase","volume":"74","author":"Keilin","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115805_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.04.016","article-title":"Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: selective inhibitors for the tumor-associated hCA IX isoform","volume":"152","author":"Ibrahim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103222","article-title":"Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors","volume":"92","author":"Yamali","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bioorg.2018.07.027","article-title":"Synthesis of novel isoindoline-1,3-dione-based oximes and benzenesulfonamide hydrazones as selective inhibitors of the tumor-associated carbonic anhydrase IX","volume":"80","author":"Abdel-Aziz","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103225","article-title":"Synthesis and comparative carbonic anhydrase inhibition of new Schiff's bases incorporating benzenesulfonamide, methanesulfonamide, and methylsulfonylbenzene scaffolds","volume":"92","author":"El-Azab","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib21","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1002\/anie.200701189","article-title":"Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste","volume":"46","author":"K\u00f6hler","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2023.115805_bib22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.bmc.2014.12.030","article-title":"Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors","volume":"23","author":"Mahon","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/5293349","article-title":"Synthesis, carbonic anhydrase II\/IX\/XII inhibition, DFT, and molecular docking studies of hydrazide-sulfonamide hybrids of 4-methylsalicyl- and acyl-substituted hydrazide","volume":"2022","author":"Khushal","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2023.115805_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/00397910903026723","article-title":"Synthesis of hydroxamic acids by activation of carboxylic acids with N,N\u2019-carbonyldiimidazole: exploring the efficiency of the method","volume":"40","author":"Usachova","year":"2010","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2023.115805_bib25","doi-asserted-by":"crossref","first-page":"21843","DOI":"10.1021\/acsomega.1c03628","article-title":"Hydroxamic acid derivatives: from synthetic strategies to medicinal chemistry applications","volume":"6","author":"Citarella","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2023.115805_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/14756366.2022.2132485","article-title":"Design and synthesis of some new benzoylthioureido benzenesulfonamide derivatives and their analogues as carbonic anhydrase inhibitors","volume":"38","author":"Oudah","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib27","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1080\/14756366.2022.2126463","article-title":"Design and synthesis of some new benzoylthioureido phenyl derivatives targeting carbonic anhydrase enzymes","volume":"37","author":"Najm","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/ml500140t","article-title":"Carbonic anhydrase inhibitors: design, synthesis, and biological evaluation of novel sulfonyl semicarbazide derivatives","volume":"5","author":"Pichake","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115805_bib29","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.bmc.2016.04.052","article-title":"Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII","volume":"24","author":"Chandak","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/jm00189a022","article-title":"Preparation and antidiabetic activity of some sulfonylurea derivatives of 3, 5-disubstituted pyrazoles","volume":"22","author":"Soliman","year":"1979","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ejmech.2011.01.060","article-title":"Synthesis and biological evaluation of some 4-functionalized-pyrazoles as antimicrobial agents","volume":"46","author":"Sharma","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cber.19270600118","article-title":"A. Vilsmeier und A. Haack: aber die Einwirkung von Halogenphosphor auf Alkyl-formanilide. Eine neue Methode zur Darstellung sekundarer und tertiarer p-Alkylamino-benzaldehyde","volume":"60","author":"Vilsmeier","year":"1927","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"10.1016\/j.ejmech.2023.115805_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6393428","article-title":"Synthesis, biological activity, and molecular modeling studies of pyrazole and triazole derivatives as selective COX-2 inhibitors","volume":"2020","author":"Assali","year":"2020","journal-title":"J. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib34","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/jm00040a010","article-title":"Anticancer specificity of some ellipticinium salts against human brain tumors in vitro","volume":"37","author":"Acton","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib35","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/acsomega.8b02849","article-title":"Design, synthesis, characterization, and antiproliferative activity of organoplatinum compounds bearing a 1,2,3-triazole ring","volume":"4","author":"Singh","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2023.115805_bib36","first-page":"2","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2023.115805_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0060017","article-title":"Cytometric analyses to distinguish death processes","volume":"6","author":"Gorczyca","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2023.115805_bib38","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1021\/acs.jmedchem.5b01343","article-title":"Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX","volume":"58","author":"Leitans","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib39","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.161301298","article-title":"Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells","volume":"98","author":"Whittington","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2023.115805_bib40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bpj.2014.06.024","article-title":"A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations","volume":"107","author":"Carpenter","year":"2014","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2023.115805_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103499","article-title":"New phosphazine and phosphazide derivatives as multifunctional ligands targeting acetylcholinesterase and \u03b2-Amyloid aggregation for treatment of Alzheimer's disease","volume":"95","author":"El-Sayed","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib42","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/ci500004h","article-title":"AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research","volume":"54","author":"Liu","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115805_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejmech.2014.02.023","article-title":"4-Functionalized 1,3-diarylpyrazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII","volume":"76","author":"Khloya","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib44","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase","volume":"246","author":"Khalifah","year":"1971","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/14756366.2016.1241781","article-title":"3D QSAR studies, pharmacophore modeling, and virtual screening of diarylpyrazole\u2013benzenesulfonamide derivatives as a template to obtain new inhibitors, using human carbonic anhydrase II as a model protein","volume":"32","author":"Entezari Heravi","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/bi00853a037","article-title":"The catalytic versatility of erythrocyte carbonic anhydrase. II. Kinetic studies of the enzyme-catalyzed hydration of pyridine aldehydes","volume":"6","author":"Pocker","year":"1967","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115805_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13050094","article-title":"Antiproliferative and carbonic anhydrase II inhibitory potential of chemical constituents from lycium shawii and aloe vera: evidence from in silico target fishing and in vitro testing","volume":"13","author":"Ur Rehman","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115805_bib48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2023.115805_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2023.115805_bib50","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2023.115805_bib51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cyto.a.10117","article-title":"New method for the analysis of cell cycle-specific apoptosis","volume":"57","author":"Tao","year":"2004","journal-title":"Cytom. Part A."},{"key":"10.1016\/j.ejmech.2023.115805_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105421","article-title":"Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia","volume":"117","author":"El-Hussieny","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104985","article-title":"Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma","volume":"112","author":"Fouad","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejmech.2019.07.029","article-title":"Design, synthesis and biological evaluation of novel \u03b1-aminophosphonate oxadiazoles via optimized iron triflate catalyzed reaction as apoptotic inducers","volume":"180","author":"Ewies","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115805_bib55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5395\/rde.2015.40.2.172","article-title":"Statistical notes for clinical researchers: post-hoc multiple comparisons","volume":"40","author":"Kim","year":"2015","journal-title":"Restor. Dent. Endod."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:58:04Z","timestamp":1759330684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S0223523423007729"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115805","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring novel anticancer pyrazole benzenesulfonamides featuring tail approach strategy as carbonic anhydrase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115805"}}